<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997148</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0150</org_study_id>
    <nct_id>NCT04997148</nct_id>
  </id_info>
  <brief_title>Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)</brief_title>
  <official_title>Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the effectiveness of cladribine tablets in a&#xD;
      UK real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">July 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate in the Year Prior to Treatment Initiation With Cladribine Tablets</measure>
    <time_frame>1 Year prior to date of Cladribine tablet initiation</time_frame>
    <description>The annualized relapse rate for a participant is defined here as the number of clinician's confirmed relapses that occurred in the year prior to the date of Cladribine tablet initiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate in the Year 1 After Treatment Initiation With Cladribine Tablets</measure>
    <time_frame>Year 1 after treatment initiation with Cladribine tablets</time_frame>
    <description>The annualized relapse rate for a participant is defined here as the number of clinician's confirmed relapses that occurred in Year 1 after treatment initiation with Cladribine tablets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate in the Year 2 After Treatment Initiation with Cladribine Tablets</measure>
    <time_frame>Year 2 after treatment initiation with Cladribine tablets</time_frame>
    <description>The annualized relapse rate for a participant is defined here as the number of clinician's confirmed relapses that occurred in Years 2 after treatment initiation with Cladribine tablets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate in the Year 3 After Treatment Initiation with Cladribine Tablets</measure>
    <time_frame>Year 3 after treatment initiation with Cladribine tablets</time_frame>
    <description>The annualized relapse rate for a participant is defined here as the number of clinician's confirmed relapses that occurred in Year 3 after treatment initiation with Cladribine tablets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate in the Year 4 After Treatment Initiation with Cladribine Tablets</measure>
    <time_frame>Year 4 after treatment initiation with Cladribine tablets</time_frame>
    <description>The annualized relapse rate for a participant is defined here as the number of clinician's confirmed relapses that occurred in Years 4 after treatment initiation with Cladribine tablets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate in the Year 5 After Treatment Initiation with Cladribine Tablets</measure>
    <time_frame>Year 5 after treatment initiation with Cladribine tablets</time_frame>
    <description>The annualized relapse rate for a participant is defined here as the number of clinician's confirmed relapses that occurred in Year 5 after treatment initiation with Cladribine tablets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Remain Relapse-Free in Each Year after Initiation of Cladribine Tablet Treatment</measure>
    <time_frame>Year 1, 2, 3, 4 and 5 after treatment initiation with Cladribine tablets</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Remain Relapse-free up to 5 years After the Initation of Caldribine Tablets</measure>
    <time_frame>Up to 5 years after the initation of Cladribine tablets</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Cladribine Tablet Initiation to First Relapse</measure>
    <time_frame>up to maximum 5 years after treatment initiation with Cladribine tablets</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Cladribine Tablets</measure>
    <time_frame>From Cladribine treatment initiation up to end of Cladribine treatment (assessed up end of Treatment Year 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received Subsequent Disease-modifying Therapies (DMTs) after Cladribine Tablets Discontinuation/Treatment Completion</measure>
    <time_frame>up to 5 years after treatment initiation with Cladribine tablets</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disability Progression Assessed by Expanded Disease Severity Scale (EDSS) at Treatment Initiation and Start of Treatment Year 2</measure>
    <time_frame>At Treatment Initiation and Start of Treatment Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disability Progression Confirmed over 6 Months, Assessed by Expanded Disease Severity Scale (EDSS) at 2 Years after Cladribine Tablet Treatment Initiation</measure>
    <time_frame>At 2 years after treatment initiation with Cladribine tablets</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Grade 3 Lymphopenia, Grade 4 Lymphopenia, Herpes Infections, Serious Infections, Opportunistic Infections and Malignancies</measure>
    <time_frame>up to maximum 5 years after treatment initiation with Cladribine tablets</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine</arm_group_label>
    <description>No intervention will be administered as a part of this study. Participants with Highly-active Disease Relapsing-remitting Multiple Sclerosis (HDA-RRMS), who completed at least Year 1 of treatment with cladribine tablets in routine clinical practice will be enrolled into this study and assessed up to maximum 5 years after cladribine tablets initiation.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with HDA-RRMS who initiated treatment with cladribine tablets.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physician diagnosis of HDA-RRMS as defined by clinical or radiological features&#xD;
&#xD;
          -  Treatment initiation with cladribine tablet monotherapy on or after 22 August 2017 and&#xD;
             at least 3 years before enrolment&#xD;
&#xD;
          -  Completion of Year 1 treatment of cladribine tablets (Week 1 and Week 2 treatment, per&#xD;
             recommended dose in Year 1: 1.75 milligrams per kilogram [mg/kg] body weight,&#xD;
             cumulatively)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received cladribine tablet treatment within an interventional clinical trial during&#xD;
             the study period&#xD;
&#xD;
          -  Received treatment with any investigational therapy for RRMS in the 6 months prior to&#xD;
             cladribine tablet treatment initiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire- Neurology</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tarunya.arun@uhcw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tarunya Arun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire Health Board- Department of Neurology</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Niall.MacDougall@lanarkshire.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Niall MacDougall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Gallagher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barking Havering and Redbridge University Hospitals NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>miriam.mattoscio@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Miriam Mattoscio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London UCL</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>wallace.brownlee1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Wallace Brownlee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital (2655)</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Nikos.Evangelou@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nikos Evangelou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>david.rog@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Rog</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0150</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Mavenclad ®</keyword>
  <keyword>Cladribine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

